Skip to product information
Adagrasib – LuciAda
KSh240,000.00
|
What it treats: |
|
|
Non-Small Cell Lung Cancer (NSCLC) |
Adagrasib is approved for adults with locally advanced or metastatic NSCLC with a KRAS G12C mutation, as detected by gene test, who have received at least one prior systemic therapy. It received accelerated approval based on the KRYSTAL-1 trial, showing an objective response rate of 43% and a median duration of response of 8.5 months |
|
Colorectal Cancer (CRC) |
Adagrasib, in combination with cetuximab, is approved for adults with locally advanced or metastatic CRC with a KRAS G12C mutation, as detected by an gene test, who have received prior chemotherapy including fluoropyrimidine, oxaliplatin, and irinotecan.
|